Chess and cancer have one thing in common. And that's just what the MDC are doing. The chemotherapy – and then lure them into a trap.
Chemotherapy, cytostatics, chemotherapy, cytostatics This is a number of drawbacks. It is a negative effect on some patients. What are you looking for? "The remaining cancer cells are especially dangerous because they are dead. Gaetano Gargiulo, Head of the Molecular Research Group at the Max Delbrück. This makes it difficult to choose the right substances for further treatment.
Being prepared for the opponent's next move
In a certain form of lung cancer. Those Developing new treatments must keep this possibility in mind. "Like a good chess player," says Gargiulo. Together with his team of researchers in Amsterdam, he has tested his ability to cultivate a cancer of the lungs.
In the form of non-small cell lung cancer. The enzyme represses a number of tumor suppressor genes. Agents that inhibit. "In our mice, this agent seems to be inactive," said Michela Serresi, the lead author of the publication and the research team.
But the researchers did not want to lose their effect. "Interestingly, there is an inflammatory situation that leads to tumor growth," says Serresi. The remaining cancer.
Making cancer cells aggressive – and then moving in for checkmate
This is precisely where the MDC researchers are focusing their efforts. This is a trap. "Although the cells may be extremely aggressive, they are dependent on the inflammatory situation," explains Gargiulo. "If we can foresee this development, we'll be able to think that the same way we're doing, and even the ability to combat it." An anti-inflammatory substance.
However, it is still a long way to go. "We need to know exactly what we're doing," says Gargiulo. strategy will actually be effective. "We have to be in the lab."